InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
2.640
+0.070 (2.72%)
At close: Nov 20, 2024, 4:00 PM
2.550
-0.090 (-3.41%)
After-hours: Nov 20, 2024, 7:31 PM EST
InspireMD Revenue
InspireMD had revenue of $1.81M in the quarter ending September 30, 2024, with 16.32% growth. This brings the company's revenue in the last twelve months to $6.82M, up 24.70% year-over-year. In the year 2023, InspireMD had annual revenue of $6.21M with 20.00% growth.
Revenue (ttm)
$6.82M
Revenue Growth
+24.70%
P/S Ratio
14.69
Revenue / Employee
$103,348
Employees
66
Market Cap
68.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
| Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
| Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
| Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
| Dec 31, 2019 | 3.72M | 120.00K | 3.33% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CytomX Therapeutics | 126.62M |
| electroCore | 23.33M |
| Forian | 19.71M |
| Cue Biopharma | 9.53M |
| Aligos Therapeutics | 6.00M |
| BeyondSpring | 1.88M |
NSPR News
- 8 days ago - InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System - GlobeNewsWire
- 6 weeks ago - InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System - GlobeNewsWire
- 2 months ago - InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System - GlobeNewsWire
- 3 months ago - InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment - GlobeNewsWire